Bristol-Myers Squibb Co vs Trump Media and Technology Group Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Trump Media and Technology Group Corp trades at $8.34 (market cap $2.48B). The key difference: Bristol-Myers Squibb Co is far larger — about 52.4× Trump Media and Technology Group Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| BMY | DJT | |
|---|---|---|
Market Cap | $129.94B | $2.48B |
Sector | Health | Media |
52-Week High | $65.89 | $18.50 |
52-Week Low | $42.60 | $7.06 |
Enterprise Value | $163.92B | $2.54B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
DJT stock trades at $8.27, down 11.93% in the last session, reflecting bearish technical signals and fundamental challenges. The company reported Q2 2026 revenue of $1.67 million with a net loss of $238.1 million, driven by digital asset declines. Technical indicators show strong bearish momentum with support at $8 and resistance at $9-10 levels.
Outlook remains challenging with unsustainable valuation metrics (P/S ratio of 547.62) and persistent cash burn. Investment opportunities are limited given negative profitability and high business execution risks. Key risks include continued losses, competitive pressures, and volatile digital asset holdings affecting financial results.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →